Goldman Throws in the Towel on Nektar After $14 Billion Drop

(Bloomberg) -- Nektar Therapeutics bull Goldman Sachs is calling it quits after recommending shares since December despite the stock’s slide and subsequent removal from the S&P 500 Index.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.